预约演示
更新于：2025-02-02
Avatrombopag Maleate
马来酸阿伐曲泊帕
更新于：2025-02-02
概要
基本信息
药物类型 小分子化药 |
别名 avatrombopag、Avatrombopag maleate (JAN/USAN)、AKR-501 + [14] |
作用机制 TPO receptor激动剂(血小板生成素受体激动剂) |
非在研适应症 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2018-05-21), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C33H38Cl2N6O7S2 |
InChIKeyMISPBGHDNZYFNM-BTJKTKAUSA-N |
CAS号677007-74-8 |
关联
103
项与 马来酸阿伐曲泊帕 相关的临床试验CTRI/2024/08/072877
An Open Label Balanced Randomized Single Dose Two Treatment Three Sequence Three Period Partial Replicate Reference Scaled Average Oral Bioequivalence Study of Avatrombopag Maleate 20 Mg Tablets Manufactured by Bdr Pharmaceuticals Internationals Pvt Ltd India with Doptelet (avatrombopag) 20 mg Tablets Manufactured By Swedish Orphan Biovitrum Ab Publ Stockholm Sweden Se 11276 In Healthy Adult Human Subjects Under Fed Conditions - Nil
JPRN-UMIN000054697
Prospective Study on the Efficacy of Avatrombopag Maleate Administration for Biliary Procedures in Chronic Liver Disease Patients with Thrombocytopenia - APBT Study
NCT06202625
Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haploidentical Hematopoietic Stem Cell Transplantation: Prospective, Multi-center, Double-blinded, Randomized Placebo-controlled Study
100 项与 马来酸阿伐曲泊帕 相关的临床结果
登录后查看更多信息
100 项与 马来酸阿伐曲泊帕 相关的转化医学
登录后查看更多信息
100 项与 马来酸阿伐曲泊帕 相关的专利（医药）
登录后查看更多信息
217
项与 马来酸阿伐曲泊帕 相关的文献（医药）2025-01-01BRITISH JOURNAL OF HAEMATOLOGY
Article
Chemotherapy‐induced thrombocytopenia (CIT) remains a common complication of cancer therapy with no approved available treatments in most of the world. Although a prior clinical trial of avatrombopag for CIT did not meet its primary end‐point, a report from Galamaga and colleagues raises prospects for a second chance for avatrombopag in CIT, highlighting the differences between nadir and persistent CIT and the importance of patient selection in CIT treatment.Commentary on: Galamaga et al. Avatrombopag for the treatment of patients with chemotherapy‐induced thrombocytopenia: a case series. Br J Haematol 2025; 206:272‐278.
2025-01-01BRITISH JOURNAL OF HAEMATOLOGY
Avatrombopag for the treatment of patients with chemotherapy‐induced thrombocytopenia: A case series
Article
作者: Acosta, Cassaundra ; Johnston, Stephanie ; Galamaga, Robert
Summary:
Management of chemotherapy‐induced thrombocytopenia (CIT) is challenging, often resulting in chemotherapy treatment delays, dose reduction, and treatment interruption. Randomized trials support the potential efficacy and safety of thrombopoietin receptor agonists in CIT management. A phase III trial of avatrombopag (AVA) demonstrated increased platelet counts (PC) in patients with solid tumours experiencing CIT. To complement those findings, this case series of six patients with solid tumours and CIT is presented. Results from these cases support the clinical benefit of AVA in improving PC and reducing the impact of CIT on tumour treatment, allowing continued therapy without dose reduction or treatment interruption.
2024-12-31ANNALS OF MEDICINE
Cyclosporine plus avatrombopag versus cyclosporine monotherapy for first-line treatment of elderly patients with transfusion-dependent non-severe aplastic anemia: a single center retrospective study
Article
作者: Chen, Miao ; Yang, Chen ; Zhang, Zhuxin ; Hu, Qinglin ; Han, Bing ; Wang, Leyu
BACKGROUND:
Elderly patients with transfusion-dependent non-severe aplastic anemia (TD-NSAA) face limited treatment options owing to transplantation incompatibility and safety concerns.
METHODS:
Data from older patients (≥60 years) newly diagnosed with TD-NSAA and had been treated with either avatrombopag (AVA) + cyclosporine (CsA) or CsA monotherapy at our center were retrospectively collected.
RESULTS:
In total, 52 patients were enrolled, with 26 receiving AVA + CsA and 26 receiving CsA monotherapy. The overall response (OR) rate was higher in the AVA + CsA group than in the CsA group at the 1st, 2nd, 3rd, 6th months, and at the end of the follow-up (all p < 0.05). The complete response (CR) rate was higher in the AVA + CsA group than in the CsA group at the 6th month and at the end of follow-up (p = 0.017 and 0.039). Patients receiving AVA + CsA had a shorter time to achieve the first response (p = 0.008) and CR (p = 0.010) than those receiving CsA monotherapy. Furthermore, patients receiving AVA + CsA exhibited a higher rate of platelet transfusion independence at the 3rd (p = 0.041), 6th (p = 0.008) months, and likewise at the end of the follow-up (p = 0.097).
CONCLUSIONS:
The addition of AVA to CsA can significantly improve the OR or CR rate and platelet levels with acceptable side effects in elderly patients, which implies that the combination is a viable alternative for elderly patients with TD-NSAA.
100 项与 马来酸阿伐曲泊帕 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性肝病 | 加拿大 | 2023-11-03 | |
| 免疫性血小板减少症 | 欧盟 | 2019-06-20 | |
| 免疫性血小板减少症 | 冰岛 | 2019-06-20 | |
| 免疫性血小板减少症 | 列支敦士登 | 2019-06-20 | |
| 免疫性血小板减少症 | 挪威 | 2019-06-20 | |
| 血小板减少症 | 美国 | 2018-05-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性血小板减少症 | 临床3期 | 中国 | 2021-03-02 | |
| 原发性血小板减少症 | 临床3期 | 中国 | 2021-03-02 | |
| 原发性血小板减少症 | 临床3期 | 中国 | 2021-03-02 | |
| 慢性特发性血小板减少性紫癜 | 临床3期 | 美国 | 2012-03-26 | |
| 慢性血小板减少症 | 临床3期 | 澳大利亚 | 2012-02-16 | |
| 慢性血小板减少症 | 临床3期 | 比利时 | 2012-02-16 | |
| 慢性血小板减少症 | 临床3期 | 保加利亚 | 2012-02-16 | |
| 慢性血小板减少症 | 临床3期 | 捷克 | 2012-02-16 | |
| 慢性血小板减少症 | 临床3期 | 荷兰 | 2012-02-16 | |
| 慢性血小板减少症 | 临床3期 | 新西兰 | 2012-02-16 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 60 | 艱襯壓顧壓繭網憲淵襯(廠糧鏇顧廠鏇醖製淵壓) = 廠壓獵製築鑰鑰製構範 鏇鬱構鏇艱淵鹹選繭鏇 (艱鑰積鏇糧製糧獵積醖, 網齋顧鏇鏇餘鹽鬱廠遞 ~ 憲醖簾艱製積鏇築齋鏇) 更多 | - | 2025-01-16 | |||
N/A | - | 壓積構顧艱鏇憲衊鹹膚(鬱簾糧糧製夢鏇獵顧鏇) = A total of 49 adverse events (AEs) were reported in 29/190 patients (15.3%) in the FAS, with 15 AEs in ten patients (5.3%) considered AVA-related. Two patients discontinued AVA treatment due to AEs, which included abdominal pain and fatigue. 鏇製簾蓋醖鹹繭顧簾廠 (網艱蓋網壓艱選壓衊衊 ) | - | 2024-12-09 | |||
N/A | 47 | 網積顧壓淵壓艱襯醖艱(觸襯積淵構觸餘膚憲夢) = 夢鹽糧鏇積窪壓醖淵衊 襯齋繭膚鹽壓窪窪醖觸 (淵衊鹹鑰遞艱艱鹽繭淵 ) 更多 | 积极 | 2024-12-08 | |||
N/A | - | 選構獵網淵廠選醖鹽鹹(鏇築襯製齋構築製艱顧) = 蓋憲夢製夢繭顧憲製範 鏇鏇網鬱壓鹹顧繭壓齋 (積廠憲壓築壓觸壓製獵 ) 更多 | - | 2024-12-08 | |||
Romiplostim | 選構獵網淵廠選醖鹽鹹(鏇築襯製齋構築製艱顧) = 窪繭鏇積繭壓積襯鹹鏇 鏇鏇網鬱壓鹹顧繭壓齋 (積廠憲壓築壓觸壓製獵 ) 更多 | ||||||
N/A | - | 鹽簾襯製簾鬱壓膚鹹築(憲築鹽壓觸簾製選齋廠) = 觸襯選築選憲蓋膚製窪 憲艱顧選膚鹹範鏇選蓋 (憲網鹹糧願膚鹽積壓簾 ) 更多 | - | 2024-12-08 | |||
Romiplostim | 鹽簾襯製簾鬱壓膚鹹築(憲築鹽壓觸簾製選齋廠) = 齋窪夢憲獵獵餘蓋製鹹 憲艱顧選膚鹹範鏇選蓋 (憲網鹹糧願膚鹽積壓簾 ) 更多 | ||||||
N/A | - | 顧醖壓築願艱醖鏇積選(遞構積鹹製餘餘繭襯鬱) = 壓醖簾構簾齋簾艱艱鑰 糧襯鹽獵鑰襯鑰糧醖膚 (衊繭簾醖齋衊獵鏇鏇艱 ) | - | 2024-12-07 | |||
临床4期 | - | 52 | 構積糧獵獵獵憲製構鏇(顧積築鑰膚積襯窪範願) = 網襯糧鬱鬱憲襯襯鹽鹹 選窪壓網餘繭蓋糧鏇範 (築獵壓齋齋簾積構獵鏇 ) | 积极 | 2024-12-07 | ||
临床4期 | 47 | 築鏇艱繭衊簾鹹觸築遞(齋觸築醖鏇餘繭範蓋壓) = 選築製憲襯衊積淵壓淵 夢願築積艱選憲顧餘鑰 (醖衊積鏇鹽網鹹淵遞糧 ) 更多 | 积极 | 2024-05-14 | |||
EHA2024 人工标引  | N/A | 20 | 範廠艱醖憲遞襯製製蓋(鏇夢鏇鏇網壓鏇鏇糧構) = 淵糧憲艱觸醖構築齋廠 築鑰窪選憲鏇淵鏇鹽糧 (範窪窪範艱願鏇醖夢膚, 34 ~ 47) 更多 | 积极 | 2024-05-14 | ||
临床3期 | 75 | 製膚醖憲窪簾網齋築顧(鏇壓壓糧觸觸鬱鏇構鑰) = 廠憲獵廠製糧蓋構鹹網 衊襯鏇觸艱蓋網遞鏇顧 (夢憲觸範鏇膚夢選窪夢 ) 达到 更多 | 积极 | 2024-05-14 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用